Dr Adam Paul Januszewski

About

Special interests

Lung Cancer
Personalised medicine
Early-stage lung cancer
Clinical trials

Languages spoken

English

Treatments and tests offered by Dr Adam Paul Januszewski at Nuffield Health

• Chemotherapy

Locations Dr Adam Paul Januszewski works with

Related experience

Research

Publications

Georgia Hardavella, Dimitrios E. Magouliotis, Roberto Chalela, Adam Januszewski, Fabio Dennstaedt, Paul Martin Putora, Alfred So, Angshu Bhowmik. Breathe 2024 20: 230219; DOI: 10.1183/20734735.0219-2023

McInnerney D, Quaife S, Cooke S, Michinson L, Pogson Z, Ricketts W, Januszewski A, Lerner A … Peak M, Nelson D (2024). Understanding the impact of distance and disadvantage on lung cancer are and outcomes: a study protocol. BMC Cancer 2;24(1):942

Popat S, Januszewski A, Ahmad T, Lewanski C …Hackshaw A, Wilson W. (2024) Long Term efficacy of first-line afatanib and the clinical utility of ctDNA monitoring in patients with suspected or confirmed EGFR mutant NSCLC who were unsuitable for chemotherapy. Br J Cancer (Submitted)

Mackay E, Patel K, Davidson C, Little J, Tipples K, Januszewski A, Ricketts W (2024). Simulation as an effective means of preparing trainees for active participation in MDT meetings. Future Healthc J. 28;11(1)

Januszewski A, Bower M. (2022). Lung cancer in people living with HIV. Lancet HIV 9(10):e670-e672

Januszewski A, Zhang YZ, Nicholson AG, Vivanco I, Popat S., Bowcock A. Comprehensive molecular characterisation of Pleomorphic Lung Carcinoma implicates trans-differentiation and generation of MET exon 14 as a late event. Paper submitted

Maher GJ, Fisher RA, Kaur B, Aguiar X, Aravind P, Cedano N, Clark J, Damon D, Ghorani E, Januszewski A, et al. (2022) Sensitive screening of single nucleotide polymorphisms in cell free DNA for diagnosis of gestational tumours. NPJ Genom Med 7(1):26

Cole YC, Zhang YZ, Gallo B, Januszewski A et al (2022). Correlation between BAP1 Localization, Driver Mutations and Patient Survival in Uveal Melanoma. Cancers. 25;14(17):4105

Baird R, Banks I, Cameron D, Chester J, Earl H, Flannagan M, Januszewski A. et al. (2016) An Association of Cancer Physicians’ strategy for improving services and outcomes for cancer patients. ECancer 10:608 

Dangoor A, Joffe J, Januszewski A, Mansi J, Cunningham D, Selby P, et al. (2016). The Association of Cancer Physicians responds to “Cancer Drugs, Survival and Ethics”. BMJ 35:i6487

Palmieri C, Macpherson IR, Yan K, Ades F, Riddle P, Ahmed R, Pwaday W, Stanley B, Shah D, Goji, Januszewski A, Lewanski C, Asher R, Lythgoe D, de Azambuja E, Beresford M, Howell SJ. (2016) Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer. Oncotarget 7(11):13209-20

Wathes R, Clifford A, Januszewski A, Urch C. (2015) Transformation of oncology inpatients: effects on length of stay and patient satisfaction. Future Hospitals Journal 2:162:165 

Smirne C, Grossi G, Pinato DJ, Burlone ME, Mauri FA, Januszewski A, Oldani A, Minisini R, Sharma R, Pirisi M. (2015) Evaluation of the red cell distribution width as a biomarker of early mortality in hepatocellular carcinoma. Dig Liver Dis. 47(6):488-94

Januszewski A, Stebbing J. (2014) Hyperthermia in cancer: is it coming of age? Lancet Oncol 15(6):565-6

Palmieri, C, Patten, D, Januszewski, A, Zucchini, G, Howell, S. (2014) Breast Cancer: Current and future endocrine therapies. Mol Cell Endocrinol. 25;382(1):695-723

Januszewski A, Tanner, N, Stebbing, J. (2014). Ethnic variation in breast cancer incidence and outcomes – the debate continues.  British Journal of Cancer.  7;110(1):4-6

Palmieri C, Misra, V., Januszewski, A., Yosef H., Ashford R.,  Keary, I., Davidson, N. Multicentre experience of non-pegylated liposomal doxorubicin (NPLD) use in the management of metastatic breast cancer (2014) Clinical Breast Cancer 14(2):85-93 

Papadatos-Pastos, D, Januszewski, A, Dalgleish, A. (2013) Revisiting the role of systemic therapies in patients with metastatic melanoma to the CNS. Expert Rev Anticancer Ther. 13(5);559-67

Januszewski, A, Jayasena, C, Comninos, A, Gabri, H, Taylor, A, Harvey R, Ghatei, M, Bloom, S, Dhillo, W. (2012) Plasma Kisspeptin: A Potential novel biomarker of tumour metastasis in patients with ovarian carcinoma. Clin Chem. 58(6);1061-3

Jayasena CN, Nijher GM, Comninos AN, Abbara A, Januszewski, A. Vaal ML, Sriskandarajah L, Murphy KG, Farzad Z, Ghatei MA, Bloom SR, Dhillo WS (2011) The Effects of Kisspeptin-10 on Reproductive Hormone Release Show Sexual Diamorphism in Humans. J Clin Endocrinol Metab, 96(12) E1963-72.

Krell J, Januszewski, A, Yan, K, Palmieri, C. (2011) Role of Fulvestrant in the management of postmenopausal breast cancer. Expert Rev Anticancer Ther, 11, 1641-52.

Palmieri, C, Januszewski, A, Stanway, S, Coombs, C. (2011) Irosustat: a first-generation steroid sulfatase inhibitor in breast cancer. Expert Rev Anticancer Ther, 11, 179-183.

Sanders, R, Xu, J, Shu, Y, Januszewski, A, Halder, S, Fidalgo, A, Sun, P, Hossain, M, Ma, D, Maze, M. (2009) Dexmedetomine inhibits isoflurane-induced neuroapoptosis in the neonatal rats. Anesthesiology, 110(5): 1077-85.

Ma, D, Williamson, P, Januszewski, A, Nogaro, MC, Hossain, M, Ong, LP, Shu, Y, Franks, NP, Maze, M. (2007) Xenon mitigates isoflurane-induced neuronal apoptosis in the developing rodent brain. Anesthesiology, 106(4)746-53. 

Published Abstracts

Minchom A, Gilding N, Tan V, Christoforou K, Rule J, Azlez A, Gomes F, Januszewski A. 2024. Real-world analysis of first-line maintenance (1LM) immunotherapy (IO) +/- pemetrexed for non-squamous (NSQ) advanced / metastatic non-small cell lung cancer lacking targetable mutations. Ann Oncol 9(S3):1-53

Nally E, Reeves A, Lerner A … Hawkins O, Wald D, Januszewski A. 2024. Widening access and addressing inequalities for patients in lung cancer consenting to systemic anti-cancer therapies. 2024. Lung Cancer 190S1

Gomes F, Gildoing N, Tan V … Aziez A, Januszewski A, Minchom A. 2024. Real-world analysis of the impact of pemetrexed in first-line management (1LM) with immunotherapy for non-squamous advanced/metastatic non-small cell lung cancer lacking targetable mutations, prior to and during the COVID-19 pandemic. Lung Cancer 190S1

Warren, M., Farooque T, Rodgers S … Januszewski A, Jones L, Giaslakiotis, 2024, The role of cellular pathology departments in the improvement of turnaround times for lung adenocarcinoma biomarker testing, 2024. Lung Cancer 190S1

Dancyger C, Renouf P, Ricketts W, Januszewski A, Hudson M, Unwin A. 2024. Co-creating a psychological prehabilitation document for people preparing for lung cancer treatments. Lung Cancer 190S1

So A, Conibear J, Januszewski A … Waller D, Wilson P, Lau K. 2024. Oesophageal EUS-guided pericardiocentesis: A therapeutic conundrum in patient with EGFR-positive metastatic lung adenocarcinoma and posterior pericardial tamponade. Lung Cancer 190S1

Cooke S, Mitchinson L, McInnerny D … Januszewski A … Knowles B, Peake M, Nelson D. 2024. Exploring the experiences of rural and coastal people with lung cancer and their informal carers in assessing and engaging in treatment: A quantitative interview study. Lung Cancer 190S1

Mitchinson L, Quaife S, Nelson D … Januszewski A … Ricketts W, McInnerny D. 2024. Barriers to and facilitators of patient engagement in the lung cancer pathway: An interview study exploring the impact of distance and disadvantage in an urban setting. Lung Cancer 190S1

Palmer J, Houston A, Macpherson H … Lau K, Ricketts W, Januszewski A. 2023. Prognostic models of recurrence-free survival in non-small cell lung cancer. JTO 18(4) S92

Patel K, Mackay E, Davidons C, Little J, Tipples K, Januszewski A, Ricketts W. 2023. The utility of high-fidelity simulation in improving trainee confidence within the lung cancer multi-disciplinary setting. Lung Cancer 178S4

Mehta A, Azhar A, Lerner A, Oxley A, Januszewski A, Conibear J. 2023. A case report of the abscopal effect in metastatic non-small cell lung cancer following the irradiation of brain metastases without concurrent immunotherapy. Lung Cancer 178S4

Taylor A, Jones J, Januszewski A, Ricketts W, Jalali S. 2023. Optimisation of patients with lung cancer suitable for systemic anticancer therapies with physiotherapy and app-based support. Lung Cancer 178S4

Chamberlain F, Sheaff M, Reeves A, Castle L, Lim L, Januszewski A. 2022. A case of lymphoepithelial carcinoma of the lung responding to treatment with pembrolizumab, paclitaxel and carboplatin. Lung Cancer 165 S74

Palmer K, Liaqat M, Mohammed A, Ting M, Wilson H, Januszewski A, Conibear J. 2022. Solitary synchronous thyroid metastasis in a patient with a primary squamous cell carcinoma of the lung. Lung Cancer 165 S73-74

Ghose A, Thagarajan R, Januszewski A, Gorgoraptis N, Everett K, Marks G, Conibear J. 2022. Opsoclonus myoclonus syndrome in small cell lung cancer: a diagnostic challenge. Lung Cancer 165 S75

Ghose A, Januszewski A, Giaslakiotis K, Thyagarajan R, Everett K, Lim F, Conibear J. 2022. A rare case of primary pulmonary NUT carcinoma with vertebral metastasis. Lung Cancer 165 S75-76

Januszewski A, Zhang YZ, Chang W, Laggner U, Bowman A, Adefila-Ideozu T, Vivanco,I, Cookson W, Moffatt M, Nicholson A, Bowcock A, Popat S. 2019. Correlation of Mutations in TP53, CDKN2A and PIK3CA with VISTA expression in Pleomorphic Lung Carcinoma. J. Thoracic Oncol. 14(10) S465-466.

Zhang YZ, Adefila-Ideozu T, Bowman A, Januszewski A, Popat S, Jordan S, Robertus J, Rice A, Moffatt M, Cookson W, Nicholson A, 2018, Differentiating Sarcomatoid Mesothelioma from Pleomorphic Carcinoma and Chest Wall Sarcoma Using GATA-3/MUC4/BAP1 IHC, Elsevier Science Inc, S758-S759

Popat S, Januszewski A, Hughes L, O'Brien M, Ahmad T, Lewanski C, Dernedde U, Jankowska P, Mulatero C, Shah R, Hicks J, Geldart T, Cominos M, Gray G, Spicer J, Bell K, Roitt S, Howarth K, Cinelli M, Green E, Morris C, Ngai Y, Hackshaw A, 2018, Multicentre Phase II Trial of First-Line Afatinib in Patients with Suspected/Confirmed EGFR Mutant NSCLC: ctDNA and Long-Term Efficacy, Elsevier Science Inc, S588-S589

Januszewski A, Zhang YZ, Chang W, Laggner U, Bowman A, Adefila-Ideozu T, Cookson W, Moffatt M, Nicholson A, Bowcock A, Popat S, 2018, Heterogeneity in MET Copy Number and Intratumoural Subsets in Pleomorphic Lung Carcinoma: Implications for MET Directed Therapy in NSCLC, Elsevier Science Inc, S430-S430

Bower, M, Pria AD, Flook M, Hayward K, Januszewski A, Williams, J, Nelson, M. (2013) Comparison of two diagnostic criteria for multicentric Castleman’s disease in 72 cases. HIV Medicine.  14(Suppl. 2) 12-77

Tharmalingham H, Januszewski A, Garland P, Regan F (2012) An audit of red cell usage and transfusion thresholds for haemato-oncology in-patients in a UK tertiary centre. British Journal of Haematology (British Society of Haematology 52nd Annual Scientific Meeting),157 (Suppl. 1) 80

Januszewski, A, Sanders, R, Halder, S, Ma, D, Maze, M. (2007) Alpha-2 adrenoceptor agonism but not GABAa receptor antagonism can attenuate isoflurane-induced neuroapoptosis. Presented at the American Society of Anesthesiology Annual Meeting. San Francisco. [Online] Available from: http://www.asaabstracts.com/strands/ asaabstracts/abstract.htm;jsessionid=222C81D931253C44290E33D873044866?year=2007&index=10&absnum=831 [Accessed 26th August 2008].

Januszewski, A, Ma, D, Halder, S, Hossain, M, Sanders, R, Maze, M. (2007) Xenon protects against the apoptotic effect of isoflurane during synaptogenesis in vitro. In: Br. J. Anaesth. (Proceedings of the Anaesthetic Research Society Meeting). Oxford University Press 98 (2), p. 295.

Nogaro, MC, Ma, D, Lim, T, Januszewski, A, Maze, M. (2006) Nitrous oxide enhances while xenon mitigates isoflurane-induced activation of the intrinsic apoptotic pathway. Presented at American Society of Anesthesiology Annual Meeting. Chicago. [Online] Available from: http://www.asaabstracts.com/strands/asaabstracts/abstract.htm;jsessionid= 5B24F5B711941EDD7B8BADFF3321362B?year=2006&index=10&absnum=1674 [Accessed 26th August 2008].

Book Chapters

Januszewski A, Popat S (2019) Emerging targets and new agents in lung cancer. Thoracic Tumours: Essentials for Clinicians, 2nd Edition, ESMO, 

Januszewski A, Popat S (2019) 5 chapters in Case Histories in Lung Cancer. Editor: Dr Himender Makker.

Januszewski A, Popat S (2018) A Patient with lung cancer who received an immune checkpoint inhibitor in the first line setting, Problem Solving in cancer immunotherapy. Clinical Publishing, Milton Keynes.

Balachandran, K, Januszewski, A, Bower, M, (2017) Oncology. Medical Masterclass Study Module. Royal College of Physicians, London

Januszewski A, Harari D, O’Brien MER, (2016) A Patient with early stage lung cancer and heart disease (ed) Problem Solving in Older Cancer Patients. Clinical Publishing, Milton Keynes

Januszewski A, Popat S (2015) Chemotherapy (ed) Lung Cancer. ERS Monograph, Sheffield

Januszewski, A, Seymour, M, Copson, E, (2016) A Patient with DNA mismatch-repair colorectal cancer (ed) Problem Solving through Precision Oncology. Clinical Publishing, Milton Keynes

Zhou, Z, Januszewski, A, Maze, M, Ma, D. (2013) Mechanisms and consequences of anesthetic-induced neuroapoptosis in the developing brain (ed) Anesthesia and the Fetus. Blackwell Publishing Ltd, Oxford

Presentations 

Januszewski A, Zhang YZ, Chang W, Laggner U, Bowman A, Adefila-Ideozu T, Nicholson A, Bowcock A, Popat S, 2020. PD-L1 expression in Pleomorphic Lung Carcinoma with STK11 mutations. Lung Cancer. 139(S1);58. 

Poster presentation at BTOG 2020.

Januszewski A, Zhang YZ, Chang W, Laggner U, Bowman A, Adefila-Ideozu T, Vivanco,I, Cookson W, Moffatt M, Nicholson A, Bowcock A, Popat S. 2019. Impact of MET variants on PD-L1 expression in Pleomorphic Lung Carcinoma. 

Oral presentation at European Lung Cancer Conference, Geneva, 2019.

Januszewski A, Chang W, Zhang YZ, Laggner U, Bowman A, Adefila-Ideozu T, Cookson W, Moffatt M, Nicholson A, Popat S, Bowcock A, 2019. Intratumoral heterogeneity in PD-L1 expression in pleomorphic lung carcinoma: implications for management of stage III disease. Lung Cancer. 127(S1);91. 

Poster presentation at BTOG 2019.

Zhang YZ, Adefila-Ideozu T, Bowman A, Januszewski A, Popat S, Jordan S, Robertus J, Rice A, Moffatt M, Cookson W, Nicholson A, 2018, Differentiating Sarcomatoid Mesothelioma from Pleomorphic Carcinoma and Chest Wall Sarcoma Using GATA-3/MUC4/BAP1 IHC, Elsevier Science Inc, S758-S759

Poster presentation at World Lung Cancer Conference, 2018

Popat S, Januszewski A, Hughes L, O'Brien M, Ahmad T, Lewanski C, Dernedde U, Jankowska P, Mulatero C, Shah R, Hicks J, Geldart T, Cominos M, Gray G, Spicer J, Bell K, Roitt S, Howarth K, Cinelli M, Green E, Morris C, Ngai Y, Hackshaw A, 2018, Multicentre Phase II Trial of First-Line Afatinib in Patients with Suspected/Confirmed EGFR Mutant NSCLC: ctDNA and Long-Term Efficacy, Elsevier Science Inc, S588-S589 

Poster presentation at World Lung Cancer Conference, 2018

Januszewski A, Zhang YZ, Chang W, Laggner U, Bowman A, Adefila-Ideozu T, Cookson W, Moffatt M, Nicholson A, Bowcock A, Popat S, 2018, Heterogeneity in MET Copy Number and Intratumoural Subsets in Pleomorphic Lung Carcinoma: Implications for MET Directed Therapy in NSCLC, Elsevier Science Inc, S430-S430

Oral presentation at World Lung Cancer Conference, 2018

Memberships

• International Association for the Study of Lung Cancer
• British Thoracic Oncology Group
• European Society of Medical Oncology
• Faculty of Medical Leadership and Management
• Association of Cancer Physicians
• Royal College of Physicians (London)
• British Medical Association

Other posts held

• Thoracic Oncologist at St Bartholomew's Hospital
• Divisional Lead for Quality and Safety (Barts Cancer Centre)
• Co-Manager of the Clinical Research Deliver Team, St Bartholomew’s Hospital
• Clinical Lead for Cancer Assessment Unit and Acute Oncology Service
• British Thoracic Oncology Group Steering Committee Member
• UK Chief Investigator for International Phase 2 and 3 trials
• UK Lung Cancer Coalition Steering Committee Member
• NICE Technology Appraiser
• Cancer Research UK Regiment-Specific Consent Forms Working Group

Insurers Dr Adam Paul Januszewski works with

Dr Adam Paul Januszewski works with the following private medical insurance providers:

• Aviva Health
• AXA Health